642 related articles for article (PubMed ID: 29203493)
1. Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.
Neely MN; Kato L; Youn G; Kraler L; Bayard D; van Guilder M; Schumitzky A; Yamada W; Jones B; Minejima E
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203493
[TBL] [Abstract][Full Text] [Related]
2. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
Meng L; Wong T; Huang S; Mui E; Nguyen V; Espinosa G; Desai J; Holubar M; Deresinski S
Pharmacotherapy; 2019 Apr; 39(4):433-442. PubMed ID: 30739349
[TBL] [Abstract][Full Text] [Related]
3. A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.
Finch NA; Zasowski EJ; Murray KP; Mynatt RP; Zhao JJ; Yost R; Pogue JM; Rybak MJ
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923869
[TBL] [Abstract][Full Text] [Related]
4. Cost-benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin.
Lee BV; Fong G; Bolaris M; Neely M; Minejima E; Kang A; Lee G; Gong CL
Clin Microbiol Infect; 2021 Sep; 27(9):1346.e1-1346.e7. PubMed ID: 33221430
[TBL] [Abstract][Full Text] [Related]
5. Vancomycin therapeutic monitoring by measured trough concentration versus Bayesian-derived area under the curve in critically ill patients with cancer.
AbuSara AK; Abdelrahman DH; Habash KI; Al-Shaer MH; Le J; Nazer LH
Pharmacol Res Perspect; 2022 Feb; 10(1):e00912. PubMed ID: 34990089
[TBL] [Abstract][Full Text] [Related]
6. Are vancomycin trough concentrations adequate for optimal dosing?
Neely MN; Youn G; Jones B; Jelliffe RW; Drusano GL; Rodvold KA; Lodise TP
Antimicrob Agents Chemother; 2014; 58(1):309-16. PubMed ID: 24165176
[TBL] [Abstract][Full Text] [Related]
7. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital.
McClure S; McElroy L; Gugkaeva Z
Am J Health Syst Pharm; 2024 May; 81(11):e283-e288. PubMed ID: 38253056
[TBL] [Abstract][Full Text] [Related]
8. Risk of Acute Kidney Injury Based on Vancomycin Target Trough Attainment Strategy: Area-Under-the-Curve-Guided Bayesian Software, Nomogram, or Trough-Guided Dosing.
Knight JM; Iso T; Perez KK; Swan JT; Janak CE; Ikwuagwu JO; Musick WL
Ann Pharmacother; 2024 Feb; 58(2):110-117. PubMed ID: 37144736
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data.
Fewel N
J Clin Pharm Ther; 2021 Oct; 46(5):1426-1432. PubMed ID: 34169543
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin dosing and target attainment in children.
Hwang D; Chiu NC; Chang L; Peng CC; Huang DT; Huang FY; Chi H
J Microbiol Immunol Infect; 2017 Aug; 50(4):494-499. PubMed ID: 26462708
[TBL] [Abstract][Full Text] [Related]
11. Examining the Relationship Between Vancomycin Area Under the Concentration Time Curve and Serum Trough Levels in Adults With Presumed or Documented Staphylococcal Infections.
Clark L; Skrupky LP; Servais R; Brummitt CF; Dilworth TJ
Ther Drug Monit; 2019 Aug; 41(4):483-488. PubMed ID: 30817704
[TBL] [Abstract][Full Text] [Related]
12. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
Pai MP; Neely M; Rodvold KA; Lodise TP
Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
[TBL] [Abstract][Full Text] [Related]
13. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
[TBL] [Abstract][Full Text] [Related]
14. AUC versus peak-trough dosing of vancomycin: applying new pharmacokinetic paradigms to an old drug.
Brown DL; Lalla CD; Masselink AJ
Ther Drug Monit; 2013 Aug; 35(4):443-9. PubMed ID: 23851909
[TBL] [Abstract][Full Text] [Related]
15. Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients.
Turner RB; Kojiro K; Shephard EA; Won R; Chang E; Chan D; Elbarbry F
Pharmacotherapy; 2018 Dec; 38(12):1174-1183. PubMed ID: 30362592
[TBL] [Abstract][Full Text] [Related]
16. VANCOmycin dose adjustments comparing trough levels to the ratio of the area under de curve to the minimum inhibitory concentration method using a BAYESian approach: A feasibility study.
Bilodeau V; Huot J; Perreault C; Haraoui LP; Delorme C; Poudrette J; Marsot A; Crevier B
J Clin Pharm Ther; 2022 Dec; 47(12):2335-2344. PubMed ID: 36461655
[TBL] [Abstract][Full Text] [Related]
17. Correlation of a Vancomycin Pharmacokinetic Model and Trough Serum Concentrations in Pediatric Patients.
Ploessl C; White C; Manasco K
Pediatr Infect Dis J; 2015 Oct; 34(10):e244-7. PubMed ID: 26121203
[TBL] [Abstract][Full Text] [Related]
18. A Strategy for Dosing Vancomycin to Therapeutic Targets Using Only Trough Concentrations.
Prybylski JP
Clin Pharmacokinet; 2017 Mar; 56(3):263-272. PubMed ID: 27389404
[TBL] [Abstract][Full Text] [Related]
19. Establishment of an AUC
Chavada R; Ghosh N; Sandaradura I; Maley M; Van Hal SJ
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242672
[TBL] [Abstract][Full Text] [Related]
20. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.
Tkachuk S; Collins K; Ensom MHH
Paediatr Drugs; 2018 Apr; 20(2):153-164. PubMed ID: 29344778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
